Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab

Laursen, Jannie; Søndergaard, Helle Bach; Sørensen, Per Soelberg; Sellebjerg, Finn; Oturai, Annette Bang

doi:10.1016/j.msard.2016.10.005

Cited by 69 publications

(47 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The authors hypothesized that treatment with IFNB might increase the serum vitamin D levels through an enhanced responsiveness to sun exposure [106]. The same authors did not find similar associations for glatiramer acetate (GA) therapy and vitamin D. More recently, Laursen et al [107] found that higher vitamin D levels in CIS may slow neurodegeneration evaluated by brain volume measures. In fact, they found that each 10 ng/mL increase in 25(OH)D was significantly associated with a 7.8 mL higher gray matter volume [108].…”

Section: Vitamin D Deficiency and Multiple Sclerosis: Role In The mentioning

confidence: 99%

“…A preliminary Iranian study assessed the safety and efficacy of high-dose vitamin D supplementation during pregnancy in women with MS [117]. The women in the vitamin D group had significantly fewer relapses during pregnancy, a tendency for fewer relapses up six months after delivery, and a more stable Expanded Disability Status Scale (EDSS) than those without supplementation [107]. In a longitudinal study [118], in which 170 natalizumab-treated patients were followed for one year between two winter seasons, patients with insufficient serum 25(OH)D levels at baseline (<20 ng/mL) were advised to take vitamin D supplements, and a significant inverse relationship with the ARR was found, as, for each nmol/L increase in 25(OH)D, a 0.014 decrease in ARR was observed.…”

Section: Vitamin D Deficiency and Multiple Sclerosis: Role In The mentioning

confidence: 99%

See 1 more Smart Citation

Vitamin D in Neurological Diseases: A Rationale for a Pathogenic Impact

Moretti

Morelli

Caruso

2018

IJMS

116

View full text Add to dashboard Cite

It is widely known that vitamin D receptors have been found in neurons and glial cells, and their highest expression is in the hippocampus, hypothalamus, thalamus and subcortical grey nuclei, and substantia nigra. Vitamin D helps the regulation of neurotrophin, neural differentiation, and maturation, through the control operation of growing factors synthesis (i.e., neural growth factor [NGF] and glial cell line-derived growth factor (GDNF), the trafficking of the septohippocampal pathway, and the control of the synthesis process of different neuromodulators (such as acetylcholine [Ach], dopamine [DA], and gamma-aminobutyric [GABA]). Based on these assumptions, we have written this review to summarize the potential role of vitamin D in neurological pathologies. This work could be titanic and the results might have been very fuzzy and even incoherent had we not conjectured to taper our first intentions and devoted our interests towards three mainstreams, demyelinating pathologies, vascular syndromes, and neurodegeneration. As a result of the lack of useful therapeutic options, apart from the disease-modifying strategies, the role of different risk factors should be investigated in neurology, as their correction may lead to the improvement of the cerebral conditions. We have explored the relationships between the gene-environmental influence and long-term vitamin D deficiency, as a risk factor for the development of different types of neurological disorders, along with the role and the rationale of therapeutic trials with vitamin D implementation.

show abstract

Section: Vitamin D Deficiency and Multiple Sclerosis: Role In The mentioning

confidence: 99%

Section: Vitamin D Deficiency and Multiple Sclerosis: Role In The mentioning

confidence: 99%

Vitamin D in Neurological Diseases: A Rationale for a Pathogenic Impact

Moretti

Morelli

Caruso

2018

IJMS

116

View full text Add to dashboard Cite

show abstract

“…In this context it should be mentioned that the individual vitamin D metabolism, which could be influenced by genetically mutations in the enzymes required for the anabolism and catabolism of vitamin D 3 as discussed before, has to be analyzed since this would influence the response to identical supplemented doses of vitamin D in different individuals [120]. Subsequent studies were able to show a reduction in relapse rate after supplementation of vitamin D 3 [121] and an improved cognitive performance [122]. Oral supplementation of 20,000 IU vitamin D 3 /week in a 96-week randomized double-blind placebo-controlled study in 68 MS patients results in reduced levels of anti-EBV nuclear antigen 1 (EBNA1) protein and fragment antibody [123].…”

Section: Multiple Sclerosismentioning

confidence: 99%

The Effects of Vitamin D Deficiency on Neurodegenerative Diseases

Lauer¹,

Janitschke²,

Hartmann³

et al. 2020

Vitamin D Deficiency

View full text Add to dashboard Cite

Approximately 90% of the elderly population in the western countries has at least a mild to moderate vitamin D hypovitaminosis. Besides the well-known function of vitamin D in calcium homeostasis, it has been recently found that several enzymes and receptors involved in its homeostasis are expressed in the nervous system and brain suggesting also an important role in the brain homeostasis. Interestingly, epidemiological and clinical studies found reduced vitamin D level associated with an increased risk of several neurodegenerative disorders. In this chapter, we focus on a potential link between vitamin D and Alzheimer's disease, Parkinson's disease, multiple sclerosis, prion disease, and motor neuron disease. Epidemiological studies were summarized, an overview of the known potential underlying pathomolecular mechanisms are given, and results from clinical studies dealing with vitamin D supplementation were presented. As an outlook, recent literature suggesting an impact of vitamin D on autism spectrum disease, depression, and schizophrenia are briefly discussed. In conclusion, the identification of an abundant vitamin D metabolism in the brain and the tight link between the increasing number of several neurological and mental disorders emphasize the need of further research making a clear recommendation of the intake and supplementation of vitamin D in a growing elderly population.

show abstract

“…Da Da die Relapsrate der RRMS 3 Monate postpartum ansteigt, die Korrektur einer Vitamin-D-Hypovitaminose jedoch zu einer Reduktion der jährlichen Schubrate führen kann, sollte dieser therapeutische Arm zur Minderung der Krankheitsaktivität nicht vernachlässigt werden [30]. Ein hoher 25(OH)-D-Serumspiegel korrelierte mit einem Rückgang des axonalen Schadens [31].…”

Section: Beobachtung Von Tpo-ak In Der Schwangerschaftunclassified

Die Post-Alemtuzumab-Therapie-induzierte Schilddrüsendysfunktion bei schubförmig-remittierender MS (RRMS) – ein variantenreiches Krankheitsbild auf einem interdisziplinären Terrain

Goischke¹

2017

Akt Neurol

View full text Add to dashboard Cite

ZusammenfassungAlemtuzumab-induzierte Schilddrüsendysfunktionen (engl.: Alemtuzumab-induced thyroid dysfunction; AITD) können die Lebensqualität von MS-Patienten wesentlich beeinträchtigen, wenn diese Nebenwirkung nicht rechtzeitig erkannt und adäquat von allen Fachrichtungen reagiert wird. Vor Alemtuzumab-Therapie sollten der TSH-Spiegel und die Schilddrüsen-AK untersucht werden. Bei Nachweis von TPO-AK vor Beginn der Behandlung betrug das Risiko 69 %, eine AITD zu entwickeln im Vergleich zu TPO-negativen Patienten mit nur 31 %.Trotzdem waren 85 %, die eine AITD später entwickelten, vor Therapie TPO-AK-negativ, sodass AK-Negativität basal kein Schutz vor AITD darstellt. Deshalb müssen die periodischen Tests streng durchgeführt werden. Eine interdisziplinäre Zusammenarbeit von Neurologen, Internisten (Endokrinologen) und Gynäkologen führt zum rechtzeitigen Erkennen des variantenreichen klinischen Verlaufes bei wechselnden biochemischen Befunden mit entsprechenden diagnostischen und therapeutischen Konsequenzen. Da die klinischen Symptome der Hypothyreose/Hyperthyreose sich mit denen der MS überschneiden können, ist die Bestimmung von laborchemischen Parametern auch im Verlauf rechtzeitig unerlässlich, insbesondere bei graviden Patientinnen. Durch die kostengünstige und gut verträgliche Add-on-Therapie mit Vitamin D mit multiplen Zielwirkungen – 1. auf die AITD, 2. auf die Reduktion der Krankheitsaktivität und 3. auf die positive Beeinflussung einer Gravidität (Verringerung einer niedrigen Geburtsgewichts-, Eklampsie- und Frühgeburtenrate, Reduktion der Übertragung der MS auf die Nachkommenschaft) – sollte trotz noch offener Fragen den Betroffenen die Chance zur Minderung der Progression nicht verwehrt werden. Der Arzt spielt eine wichtige Rolle in der Stärkung der Fähigkeit der Patienten, ihre eigene Krankheit zu managen, um die Krankheitsprogression zu vermindern. Im Arzt-Patienten-Gespräch sollte die Reduzierung von Risikofaktoren (z.B. Vit.-D-Mangel) thematisiert werden. Ein Engagement für ein optimales interdisziplinäres Management mit Therapieindividualisierung und Reduzierung von Arzneimittelnebenwirkungen verbessert die Lebensqualität von MS-Patienten.

show abstract

Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab

Cited by 69 publications

References 30 publications

Vitamin D in Neurological Diseases: A Rationale for a Pathogenic Impact

Vitamin D in Neurological Diseases: A Rationale for a Pathogenic Impact

The Effects of Vitamin D Deficiency on Neurodegenerative Diseases

Die Post-Alemtuzumab-Therapie-induzierte Schilddrüsendysfunktion bei schubförmig-remittierender MS (RRMS) – ein variantenreiches Krankheitsbild auf einem interdisziplinären Terrain

Contact Info

Product

Resources

About